Trial Profile
Lorlatinib - PF-06463922
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 19 May 2020
Price :
$35
*
At a glance
- Drugs Lorlatinib (Primary)
- Indications Neuroblastoma; Non-small cell lung cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Pfizer
- 13 May 2020 Status changed from recruiting to completed.
- 29 Apr 2017 New trial record